{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:47:29Z","timestamp":1790754449900,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.nmd.2022.12.008","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T11:40:05Z","timestamp":1671104405000},"page":"208-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of restricted access to, and low awareness of, mexiletine on people with myotonia: a real-world European survey"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2941-7988","authenticated-orcid":false,"given":"Jordi","family":"D\u00edaz-Manera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Andoni","family":"Urtizberea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Schey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"von Gallwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Whiting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Zozulya-Weidenfeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2022.12.008_bib0001","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/978-90-481-9485-8_18","article-title":"Hereditary channelopathies in neurology","volume":"686","author":"Jurkat-Rott","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.nmd.2022.12.008_bib0002","doi-asserted-by":"crossref","first-page":"e1045","DOI":"10.1212\/WNL.0000000000011425","article-title":"Population-based prevalence of myotonic dystrophy type 1 using genetic analysis of statewide blood screening program","volume":"96","author":"Johnson","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2022.12.008_bib0003","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1212\/CON.0000000000000793","article-title":"Myotonic muscular dystrophies","volume":"25","author":"Johnson","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.nmd.2022.12.008_bib0004","first-page":"98","article-title":"Diagnostics and therapy of muscle channelopathies \u2013 guidelines of the Ulm Muscle Centre","volume":"27","author":"Lehmann-Horn","year":"2008","journal-title":"Acta Myol"},{"key":"10.1016\/j.nmd.2022.12.008_bib0005","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/mus.26887","article-title":"Guidelines on clinical presentation and management of nondystrophic myotonias","volume":"62","author":"Stunnenberg","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2022.12.008_bib0006","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/WCO.0000000000000128","article-title":"Myotonic dystrophy: diagnosis, management and new therapies","volume":"27","author":"Turner","year":"2014","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.nmd.2022.12.008_bib0007","article-title":"Drug treatment for myotonia","volume":"1","author":"Trip","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nmd.2022.12.008_bib0008","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.expneurol.2013.12.005","article-title":"Nondystrophic myotonia: challenges and future directions","volume":"253","author":"Trivedi","year":"2014","journal-title":"Exp Neurol"},{"key":"10.1016\/j.nmd.2022.12.008_bib0009","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jmg.35.4.293","article-title":"Myotonia congenita in northern Finland: an epidemiological and genetic study","volume":"35","author":"Baumann","year":"1998","journal-title":"J Med Genet"},{"key":"10.1016\/j.nmd.2022.12.008_bib0010","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/sj.ejhg.5200736","article-title":"Spectrum of CLCN1 mutations in patients with myotonia congenita in Northern Scandinavia","volume":"9","author":"Sun","year":"2001","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.nmd.2022.12.008_bib0011","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.nmd.2016.12.005","article-title":"Prevalence of myotonic dystrophy type 1 in adults in western Sweden","volume":"27","author":"Lindberg","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2022.12.008_bib0012","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1212\/WNL.0000000000003504","article-title":"A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland","volume":"88","author":"Lefter","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2022.12.008_bib0013","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000444018","article-title":"An age-standardized prevalence estimate and a sex and age distribution of myotonic dystrophy types 1 and 2 in the Rome province, Italy","volume":"46","author":"Vanacore","year":"2016","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.nmd.2022.12.008_bib0014","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1093\/brain\/awp236","article-title":"Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population","volume":"132","author":"Norwood","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2022.12.008_bib0015","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1212\/WNL.0b013e31828cf8d0","article-title":"Prevalence study of genetically defined skeletal muscle channelopathies in England","volume":"80","author":"Horga","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2022.12.008_bib0016","doi-asserted-by":"crossref","first-page":"e01948","DOI":"10.1002\/brb3.1948","article-title":"The prevalence of hereditary neuromuscular disorders in Northern Norway","volume":"11","author":"M\u00fcller","year":"2021","journal-title":"Brain Behav"},{"key":"10.1016\/j.nmd.2022.12.008_bib0017","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.nmd.2018.03.006","article-title":"Prevalence and mutation spectrum of skeletal muscle channelopathies in the Netherlands","volume":"28","author":"Stunnenberg","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2022.12.008_bib0018","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/mus.26420","article-title":"The myotonic dystrophy experience: a North American cross-sectional study","volume":"59","author":"Hagerman","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2022.12.008_bib0019","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/mus.20923","article-title":"Differential diagnosis of myotonic disorders","volume":"37","author":"Miller","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2022.12.008_bib0020","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/j.1468-1331.2012.03751.x","article-title":"Measuring quality of life impairment in skeletal muscle channelopathies","volume":"19","author":"Sansone","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2022.12.008_bib0021","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.nmd.2010.08.006","article-title":"Health supervision and anticipatory guidance in adult myotonic dystrophy type 1","volume":"20","author":"Gagnon","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2022.12.008_bib0022","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.nmd.2011.03.013","article-title":"Myotonic dystrophy type 2 (DM2) and related disorders: report of the 180th ENMC workshop including guidelines on diagnostics and management 3\u20135 December 2010, Naarden, The Netherlands","volume":"21","author":"Udd","year":"2011","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2022.12.008_bib0023","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/mus.23683","article-title":"The diagnosis and treatment of myotonic disorders","volume":"47","author":"Heatwole","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2022.12.008_bib0024","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1212\/CPJ.0000000000000531","article-title":"Consensus-based care recommendations for adults with myotonic dystrophy type 1","volume":"8","author":"Ashizawa","year":"2018","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.nmd.2022.12.008_bib0025","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/CPJ.0000000000000645","article-title":"Consensus-based care recommendations for adults with myotonic dystrophy type 2","volume":"9","author":"Schoser","year":"2019","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.nmd.2022.12.008_bib0026","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1212\/CPJ.0000000000000646","article-title":"Consensus-based care recommendations for congenital and childhood-onset myotonic dystrophy type 1","volume":"9","author":"Johnson","year":"2019","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.nmd.2022.12.008_bib0027","series-title":"Myotonic dystrophies, non-dystrophic myotonia and periodic paralysis","year":"2017"},{"key":"10.1016\/j.nmd.2022.12.008_bib0028","first-page":"665","article-title":"Myotonie avec faiblesse musculaire corrig\u00e9e par l'exercice. Effet th\u00e9rapeutique de la mexil\u00e9tine [Myotonia with muscular weakness corrected by exercise. The therapeutic effect of mexiletine]","volume":"139","author":"Pouget","year":"1983","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nmd.2022.12.008_bib0029","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1212\/WNL.0b013e3181dc1a3a","article-title":"Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1","volume":"74","author":"Logigian","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2022.12.008_bib0030","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/jama.2012.12607","article-title":"Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial","volume":"308","author":"Statland","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.nmd.2022.12.008_bib0031","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jamaneurol.2015.2338","article-title":"Long-term safety and efficacy of mexiletine for patients with skeletal muscle channelopathies","volume":"72","author":"Suetterlin","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nmd.2022.12.008_bib0032","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1600-0404.2011.01587.x","article-title":"Development of a disability scale for myotonic dystrophy type 1","volume":"125","author":"Contardi","year":"2012","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.nmd.2022.12.008_bib0033","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.nmd.2021.06.010","article-title":"Efficacy and safety of mexiletine in non-dystrophic myotonias: a randomised, double-blind, placebo-controlled, cross-over study","volume":"31","author":"Vicart","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2022.12.008_bib0034","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3233\/JND-200582","article-title":"Targeted therapies for skeletal muscle ion channelopathies: systematic review and steps towards precision medicine","volume":"8","author":"Desaphy","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2022.12.008_bib0035","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/jama.2012.12906","article-title":"Mexiletine for treatment of myotonia: a trial triumph for rare disease networks","volume":"308","author":"Hoffman","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.nmd.2022.12.008_bib0036","series-title":"Namuscla SmPC","year":"2022"},{"key":"10.1016\/j.nmd.2022.12.008_bib0037","unstructured":"European Medicines Agency. Namuscla. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/namuscla [accessed 4 January 2023]."},{"key":"10.1016\/j.nmd.2022.12.008_bib0038","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.nmd.2019.08.012","article-title":"High incidence of falls in patients with myotonic dystrophy type 1 and 2: a prospective study","volume":"29","author":"Berends","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2022.12.008_bib0039","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.nmd.2017.12.010","article-title":"Falls and resulting fractures in myotonic dystrophy: results from a multinational retrospective survey","volume":"28","author":"Jim\u00e9nez-Moreno","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2022.12.008_bib0040","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jns.2016.04.018","article-title":"Quality of life in patients with myotonic dystrophy type 2","volume":"365","author":"Rakocevic Stojanovic","year":"2016","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2022.12.008_bib0041","first-page":"37","article-title":"Understanding the impact of non-dystrophic myotonia on patients and caregivers: results from a burden of disease healthcare survey","volume":"6","author":"D\u00edaz-Manera","year":"2021","journal-title":"EMJ"},{"key":"10.1016\/j.nmd.2022.12.008_bib0042","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13023-016-0417-z","article-title":"Disease awareness in myotonic dystrophy type 1: an observational cross-sectional study","volume":"11","author":"Baldanzi","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2022.12.008_bib0043","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1001\/archneur.61.12.1943","article-title":"Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1","volume":"61","author":"Modoni","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2022.12.008_bib0044","doi-asserted-by":"crossref","DOI":"10.1002\/mus.26066","article-title":"Myotonic dystrophy patient preferences in patient-reported outcome measures","author":"Heatwole","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2022.12.008_bib0045","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3389\/fneur.2020.00593","article-title":"Genotype\u2013phenotype correlations and characterization of medication use in inherited myotonic disorders","volume":"11","author":"Meyer","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2022.12.008_bib0046","series-title":"Drugs in neurology","first-page":"111","article-title":"Disorders of muscle and neuromuscular junction","author":"Nageshwaran","year":"2017"},{"key":"10.1016\/j.nmd.2022.12.008_bib0047","unstructured":"European Medicines Agency. Orphan maintenance assessment report: namuscla (mexiletine hydrochloride) treatment of myotonic disorders. EU\/3\/14\/1353 (EMA\/OD\/074\/14). https:\/\/www.ema.europa.eu\/en\/documents\/orphan-maintenance-report\/namuscla-orphan-maintenance-assessment-report-initial-authorisation_en.pdf [accessed 4 January 2023]."}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896622007325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896622007325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:13:27Z","timestamp":1760775207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896622007325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0960896622007325"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2022.12.008","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of restricted access to, and low awareness of, mexiletine on people with myotonia: a real-world European survey","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2022.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}